Title:
HUMAN ANTIBODIES SPECIFIC TO KDR AND USES THEREOF
Document Type and Number:
WIPO Patent Application WO2003075840
Kind Code:
A3
Abstract:
The invention provides antibodies that bind to KDR with an affinity comparable to or higher than human VEGF, and that neutralize activation of KDR. Antibodies include whole immunoglobulins, monovalent Fabs and single chain antibodies, multivalent single chain antibodies, diabodies, triabodies, and single domain antibodies. The invention further provides nucleic acids and host cells that encode and express these antibodies. The invention further provides a method of neutralizing the activation of KDR, a method of inhibiting angiogenesis in a mammal and a method of inhibiting tumor growth in a mammal.
More Like This:
| WO/1992/008789 | MEASLES VIRUS RECOMBINANT POXVIRUS VACCINE |
| WO/2003/027638 | METHODS FOR DETECTING GENETIC MOSAICISMS USING ARRAYS |
| JP2014513791 | Methods for identifying cosmetics for skin care compositions |
Inventors:
ZHU ZHENPING (US)
Application Number:
PCT/US2003/006459
Publication Date:
April 29, 2004
Filing Date:
March 04, 2003
Export Citation:
Assignee:
IMCLONE SYSTEMS INC (US)
ZHU ZHENPING (US)
ZHU ZHENPING (US)
International Classes:
C12N15/09; A61K39/395; A61K45/00; A61P35/00; A61P43/00; C07K16/28; C12N1/15; C12N1/19; C12N1/21; C12N5/10; (IPC1-7): C07H21/04; C07K16/00; C12N15/63; C12N15/85; C12N15/86
Foreign References:
| US20030108545A1 | 2003-06-12 |
Other References:
LU D. ET AL: "Selection of high affinity human neutralizing antibodies to VEGFR2 from a large antibody phage display library for antiangiogenesis therapy", INT. J. CANCER, vol. 97, January 2002 (2002-01-01), pages 393 - 399, XP002974290
Download PDF: